2210 related articles for article (PubMed ID: 23973293)
1. Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease.
McClean PL; Hölscher C
Neuropharmacology; 2014 Jan; 76 Pt A():57-67. PubMed ID: 23973293
[TBL] [Abstract][Full Text] [Related]
2. Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease.
McClean PL; Hölscher C
Neuropharmacology; 2014 Nov; 86():241-58. PubMed ID: 25107586
[TBL] [Abstract][Full Text] [Related]
3. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease.
McClean PL; Parthsarathy V; Faivre E; Hölscher C
J Neurosci; 2011 Apr; 31(17):6587-94. PubMed ID: 21525299
[TBL] [Abstract][Full Text] [Related]
4. The incretin analogue D-Ala2GIP reduces plaque load, astrogliosis and oxidative stress in an APP/PS1 mouse model of Alzheimer's disease.
Duffy AM; Hölscher C
Neuroscience; 2013 Jan; 228():294-300. PubMed ID: 23103794
[TBL] [Abstract][Full Text] [Related]
5. Prophylactic liraglutide treatment prevents amyloid plaque deposition, chronic inflammation and memory impairment in APP/PS1 mice.
McClean PL; Jalewa J; Hölscher C
Behav Brain Res; 2015 Oct; 293():96-106. PubMed ID: 26205827
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on β-Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimer's Disease.
Hansen HH; Fabricius K; Barkholt P; Kongsbak-Wismann P; Schlumberger C; Jelsing J; Terwel D; Termont A; Pyke C; Knudsen LB; Vrang N
PLoS One; 2016; 11(7):e0158205. PubMed ID: 27421117
[TBL] [Abstract][Full Text] [Related]
7. D-Ala2GIP facilitated synaptic plasticity and reduces plaque load in aged wild type mice and in an Alzheimer's disease mouse model.
Faivre E; Hölscher C
J Alzheimers Dis; 2013; 35(2):267-83. PubMed ID: 23568101
[TBL] [Abstract][Full Text] [Related]
8. Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice.
Gengler S; McClean PL; McCurtin R; Gault VA; Hölscher C
Neurobiol Aging; 2012 Feb; 33(2):265-76. PubMed ID: 20359773
[TBL] [Abstract][Full Text] [Related]
9. The effect of focal brain injury on beta-amyloid plaque deposition, inflammation and synapses in the APP/PS1 mouse model of Alzheimer's disease.
Collins JM; King AE; Woodhouse A; Kirkcaldie MT; Vickers JC
Exp Neurol; 2015 May; 267():219-29. PubMed ID: 25747037
[TBL] [Abstract][Full Text] [Related]
10. Neuroprotective effects of a triple GLP-1/GIP/glucagon receptor agonist in the APP/PS1 transgenic mouse model of Alzheimer's disease.
Tai J; Liu W; Li Y; Li L; Hölscher C
Brain Res; 2018 Jan; 1678():64-74. PubMed ID: 29050859
[TBL] [Abstract][Full Text] [Related]
11. Liraglutide and a lipidized analog of prolactin-releasing peptide show neuroprotective effects in a mouse model of β-amyloid pathology.
Holubová M; Hrubá L; Popelová A; Bencze M; Pražienková V; Gengler S; Kratochvílová H; Haluzík M; Železná B; Kuneš J; Hölscher C; Maletínská L
Neuropharmacology; 2019 Jan; 144():377-387. PubMed ID: 30428311
[TBL] [Abstract][Full Text] [Related]
12. The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-β plaque and glial pathology in a mouse model of Alzheimer's disease.
Long-Smith CM; Manning S; McClean PL; Coakley MF; O'Halloran DJ; Holscher C; O'Neill C
Neuromolecular Med; 2013 Mar; 15(1):102-14. PubMed ID: 23011726
[TBL] [Abstract][Full Text] [Related]
13. The incretin hormones glucagonlike peptide 1 and glucose-dependent insulinotropic polypeptide are neuroprotective in mouse models of Alzheimer's disease.
Hölscher C
Alzheimers Dement; 2014 Feb; 10(1 Suppl):S47-54. PubMed ID: 24529525
[TBL] [Abstract][Full Text] [Related]
14. Progressive age-related development of Alzheimer-like pathology in APP/PS1 mice.
Trinchese F; Liu S; Battaglia F; Walter S; Mathews PM; Arancio O
Ann Neurol; 2004 Jun; 55(6):801-14. PubMed ID: 15174014
[TBL] [Abstract][Full Text] [Related]
15. The flavonoid baicalein rescues synaptic plasticity and memory deficits in a mouse model of Alzheimer's disease.
Gu XH; Xu LJ; Liu ZQ; Wei B; Yang YJ; Xu GG; Yin XP; Wang W
Behav Brain Res; 2016 Sep; 311():309-321. PubMed ID: 27233830
[TBL] [Abstract][Full Text] [Related]
16. Effects of accelerated senescence on learning and memory, locomotion and anxiety-like behavior in APP/PS1 mouse model of Alzheimer's disease.
Lok K; Zhao H; Zhang C; He N; Shen H; Wang Z; Zhao W; Yin M
J Neurol Sci; 2013 Dec; 335(1-2):145-54. PubMed ID: 24095271
[TBL] [Abstract][Full Text] [Related]
17. Impairment of Spike-Timing-Dependent Plasticity at Schaffer Collateral-CA1 Synapses in Adult APP/PS1 Mice Depends on Proximity of Aβ Plaques.
Garad M; Edelmann E; Leßmann V
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33573114
[TBL] [Abstract][Full Text] [Related]
18. The effect of ageing on neurogenesis and oxidative stress in the APP(swe)/PS1(deltaE9) mouse model of Alzheimer's disease.
Hamilton A; Holscher C
Brain Res; 2012 Apr; 1449():83-93. PubMed ID: 22418058
[TBL] [Abstract][Full Text] [Related]
19. Cholinergic degeneration is associated with increased plaque deposition and cognitive impairment in APPswe/PS1dE9 mice.
Laursen B; Mørk A; Plath N; Kristiansen U; Bastlund JF
Behav Brain Res; 2013 Mar; 240():146-52. PubMed ID: 23178660
[TBL] [Abstract][Full Text] [Related]
20. Colivelin Ameliorates Impairments in Cognitive Behaviors and Synaptic Plasticity in APP/PS1 Transgenic Mice.
Wu M; Shi H; He Y; Yuan L; Qu X; Zhang J; Wang Z; Cai H; Qi J
J Alzheimers Dis; 2017; 59(3):1067-1078. PubMed ID: 28731445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
